Drug Profile


Alternative Names: BYM-338

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Type II-B activin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Inclusion body myositis
  • Phase II Cachexia; Muscular atrophy; Type 2 diabetes mellitus

Most Recent Events

  • 12 Jan 2017 Phase-II clinical trials in Type-2 diabetes mellitus in USA (IV) (NCT03005288)
  • 28 Dec 2016 Novartis plans a phase II trial for Type-2 diabetes mellitus in USA (NCT03005288)
  • 11 Nov 2016 Efficacy and adverse events data from the phase II/III RESILIENT trial in Inclusion body myositis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top